Jeffrey W. Albers - 22 Nov 2023 Form 4/A - Amendment Insider Report for Spyre Therapeutics, Inc. (SYRE)

Role
Director
Signature
/s/ Heidy King-Jones, as Attorney-in-Fact
Issuer symbol
SYRE
Transactions as of
22 Nov 2023
Net transactions value
$0
Form type
4/A - Amendment
Filing time
08 Dec 2023, 16:07:38 UTC
Date Of Original Report
27 Nov 2023
Previous filing
03 Nov 2023
Next filing
28 Nov 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SYRE Common Stock Conversion of derivative security $0 +34,360 $0.000000 34,360 24 Nov 2023 By Sessions LLC F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SYRE Stock Option (Right to Buy) Award $0 +50,000 $0.000000 50,000 22 Nov 2023 Common Stock 50,000 $10.39 Direct F2
transaction SYRE Series A Preferred Stock Conversion of derivative security $0 -859 -100% $0.000000* 0 24 Nov 2023 Common Stock 34,360 By Sessions LLC F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Following stockholder approval of the conversion of Series A Preferred Stock into shares of Common Stock, each share of Series A Preferred Stock automatically converted on November 24, 2023 into 40 shares of Common Stock, subject to certain limitations.
F2 This option represents a right to purchase 50,000 shares of the Issuer's Common Stock, which will vest and become exercisable in 36 equal monthly installments beginning on November 22, 2023 until such time as the option is 100% vested, subject to the Reporting Person's continuous service with the Issuer at each vesting date.

Remarks:

This amendment is being filed to report the conversion of the shares of Series A Preferred Stock, which was inadvertently omitted in the original Form 4.